BioAtla, Inc.
BCABNext catalyst
BA3011
Ovarian Cancer
Get an email about BCAB's next catalysts
Track BioAtla (BCAB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 0 past
BA3011 Phase 2 Est. Readout (IPROC)
Estimated primary completion for BA3011 trial (NCT04918186) in Ovarian Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
CAB-AXL-ADC
Undifferentiated Pleomorphic Sarcoma
BA3071
NSCLC
CAB-ROR2-ADC
Non Small Cell Lung Cancer
Ozuriftamab Vedotin
Head and Neck Cancer
PD-1 inhibitor
Non-Small-Cell Lung Cancer
BA3011
Ovarian Cancer
Pemetrexed (Alimta)
NSCLC
BA3021
Ovarian Cancer
ENB003
Ovarian Cancer
Evalstotug (BA3071)
Head and Neck Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CAB-AXL-ADC | Phase 2 | Undifferentiated Pleomorphic Sarcoma | - | - |
BA3071 | Phase 2 | NSCLC | - | - |
CAB-ROR2-ADC | Phase 2 | Non Small Cell Lung Cancer | - | - |
Ozuriftamab Vedotin | Phase 2 | Head and Neck Cancer | - | - |
PD-1 inhibitor | Phase 2 | Non-Small-Cell Lung Cancer | - | - |
BA3011 | Phase 2 | Ovarian Cancer | - | - |
Pemetrexed (Alimta) | Phase 2 | NSCLC | - | - |
BA3021 | Phase 2 | Ovarian Cancer | - | - |
ENB003 | Phase 2 | Ovarian Cancer | - | - |
Evalstotug (BA3071) | Phase 2 | Head and Neck Cancer | - | - |
Frequently asked questions
What is in BioAtla, Inc.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in BioAtla, Inc.'s (BCAB) pipeline across Phase 2. Its lead program is BA3011 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioAtla, Inc.'s next FDA catalyst?→
BioAtla, Inc.'s (BCAB) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BCAB biotech catalysts?→
Add BCAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioAtla, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.